Metformin May Slow Aging by Activating AMPK

Metformin, the most commonly prescribed medication for type 2 diabetes, is known for its safety, low cost and effectiveness in lowering blood sugar and improving insulin sensitivity. The drug works by mimicking a cellular energy deficit, similar to the state of fasting, which activates the AMP‑activated protein kinase (AMPK) pathway. AMPK promotes cellular waste clearance and repair mechanisms, thereby helping to maintain metabolic health.

A recent review of preclinical and clinical studies has highlighted the possibility that metformin’s activation of AMPK could also mitigate certain biological processes associated with aging. By enhancing cellular cleanup and repair, the drug may slow age‑related decline in tissue function, suggesting a potential role beyond glucose control. The authors note that while the data are promising, further research is needed to confirm these anti‑aging effects in humans.

If future trials confirm metformin’s benefits for aging, the drug could become a low‑cost intervention for age‑related health maintenance. For now, its established use in diabetes management remains the primary indication, with anti‑aging applications still under investigation.